Other antibodies, such as Cetuximab(anti-EGFR), Pertuzumab(anti-HER2), and bispecific antibodies-Catumaxomab, have opened new avenues in clinical research for gastrointestinal and breast cancer treatments (175). This evidence concerns the gene EGFR and breast carcinoma.